GlassScriptPhysician profile
Rana Ali
NPI 1619083177
$9,208.42
in general payments reported to CMS, 2019-2025
37 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $461 · 2021: $501 · 2022: $1,111 · 2023: $2,069 · 2024: $2,450 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,190 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,190.25 |
| Education | $248.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,058.39 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,169.67 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Philips North America LLC | $858.17 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Harmony Biosciences LLC | $698.66 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $672.65 | 2022-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $467.61 | 2019-2025 | |
| Genzyme Corporation | $467.14 | 2020-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $464.57 | 2024-2025 | Lumryz |
| Mylan Specialty L.P. | $365.51 | 2019-2024 | Yupelri |
| Amgen INC. | $294.77 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $281.36 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.12 | 2019-2025 | Ofev |
| Viatris Specialty LLC | $170.14 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $130.92 | 2024-2025 | Aralast, Hyqvia |
| Actelion Pharmaceuticals US, INC. | $123.18 | 2020-2025 | Uptravi, Opsumit |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $110.03 | 2020-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $94.73 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $79.81 | 2023-2024 | Tyvaso, Orenitram, Remodulin |
| Sanofi-Aventis U.S. LLC | $57.99 | 2022 | |
| Sunovion Pharmaceuticals INC. | $51.22 | 2019-2020 | |
| Pulmonx Corporation | $41.36 | 2022 | |
| Electromed, INC. | $34.56 | 2019-2023 | Smartvest |
| Axsome Therapeutics, INC. | $34.11 | 2024-2025 | Sunosi |
| Genentech USA, INC. | $33.03 | 2019-2023 | Xolair |
| Merck Sharp & Dohme LLC | $30.06 | 2021-2023 | |
| Insmed, INC. | $28.97 | 2019-2025 | Arikayce |
| Covis Pharma Gmbh | $26.74 | 2021 | |
| Lilly USA, LLC | $20.56 | 2025 | Zepbound |
| Verona Pharma, INC. | $17.70 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $17.38 | 2024 | |
| Mallinckrodt Hospital Products INC. | $15.07 | 2023 | Acthar |
| Paratek Pharmaceuticals, INC. | $14.66 | 2024 | Nuzyra |
| Vifor Pharma, INC. | $13.77 | 2024 | Zemaira |
| Pfizer INC. | $13.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.54 | 2024 | |
| Horizon Therapeutics Plc | $12.80 | 2020 | |
| Optinose US, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rana Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.